

References

1. Giannakeas V., Kotsopoulos, J., Cheung MC. et al. Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period. *JAMA Netw Open.* 2022;5(1):e2141633. o <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787932>
 2. Nøst TH, Alcalá K, Urbarova I, Byrne KS, Guida F, Sandanger TM, Johansson M. Systemic inflammation markers and cancer incidence in the UK Biobank. *Eur J Epidemiol.* 2021 Aug;36(8):841-848. o <https://pubmed.ncbi.nlm.nih.gov/34036468/>
 3. Yang, D., Li, H., Sun, X. et al. Clinical usefulness of high levels of C-reactive protein for diagnosing epithelial ovarian cancer. *Sci Rep* 10, 20056 (2020). o <https://www.nature.com/articles/s41598-020-77167-y>
 4. Inoguchi, T., Nohara, Y., Nojiri, C. et al. Association of serum bilirubin levels with risk of cancer development and total death. *Sci Rep* 11, 13224 (2021). o <https://www.nature.com/articles/s41598-021-92442-2>
 5. Funston, G., Hamilton, W., Abel, G., Crosbie, E.J., Rous, B. and Walter, F.M., 2020. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. *PLoS medicine*, 17(10), p.e1003295. <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003295>
 6. Pérez-Ibave DC, Burciaga-Flores CH, Elizondo-Riojas MÁ. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: A review. *Cancer Epidemiology.* 2018; 54:48-55 o <https://www.sciencedirect.com/science/article/pii/S187782118300936>
 7. Black, M.H., Giai, M., Ponzzone, R., Sismondi, P., Yu, H. and Diamandis, E.P., 2000. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. *Clinical cancer research*, 6(2), pp.467-473. o <https://aacrjournals.org/clinccancerres/article/6/2/467/287977/Serum-Total-and-Free-Prostate-specific-Antigen-for>
 8. Klein, E.A., Richards, D., Cohn, A., Tummala, M., Lapham, R., Cosgrove, D., Chung, G., Clement, J., Gao, J., Hunkapiller, N. and Jamshidi, A., 2021. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. *Annals of Oncology*, 32(9), pp.1167-1177. o <https://www.sciencedirect.com/science/article/pii/S0923753421020469>
 9. Cohen, J.D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A.A., Wong, F., Mattox, A. and Hruban, R.H., 2018. Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science*, 359(6378), pp.926-930. <https://www.science.org/doi/abs/10.1126/science.aar3247>
 10. Wan, N., Weinberg, D., Liu, T.Y., Niehaus, K., Ariazi, E.A., Delubac, D., Kannan, A., White, B., Bailey, M., Bertin, M. and Boley, N., 2019. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA. *BMC cancer*, 19(1), pp.1-10. <https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6003-8>
 11. Lee, J., Kim, H.C., Kim, S.T. et al. Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC). https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.3536
-